Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2024-05-31 00:00:00 ET · period of report 2024-02-16 · accession 0001062993-24-011568 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-31 | 2024-02-16 | LRMR | Hamilton Thomas Edward | Dir | P - Purchase | $8.74 | +57.2K | 564.8K | +11% | +$500.0K |
| D | 2024-05-31 | 2024-05-29 | LRMR | Hamilton Thomas Edward | Dir | A - Grant | $0.00 | +19.0K | 19.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-16 | P | A | 57,208 | $8.74 | 564,798 | D | — | — | (F1) Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. (the "Company") at the offering price, which closed on February 16, 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-05-29 | A | A | 19,000 | $0.00 | 19,000 | D | $7.07 · — to 2034-05-29 | 19,000 Common Stock | (F2) The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. |